Forty-one patients (41%) were obese, 35 (35%) had hypertension, 45 (45%) had been diagnosed with dyslipidaemia and prescribed statins, nine (9%) had T2DM, 21 (21%) used SGLT2 inhibitors, and 16 (16%) were on systemic corticosteroids. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.